0001213900-17-007038.txt : 20170630 0001213900-17-007038.hdr.sgml : 20170630 20170630160347 ACCESSION NUMBER: 0001213900-17-007038 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170630 DATE AS OF CHANGE: 20170630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Therapix Biosciences Ltd. CENTRAL INDEX KEY: 0001611746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1213 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38041 FILM NUMBER: 17942087 BUSINESS ADDRESS: STREET 1: 5 AZRIELI CENTER (SQUARE TOWER) CITY: TEL-AVIV STATE: L3 ZIP: 6702501 BUSINESS PHONE: 972-3-6167055 MAIL ADDRESS: STREET 1: 5 AZRIELI CENTER (SQUARE TOWER) CITY: TEL-AVIV STATE: L3 ZIP: 6702501 6-K 1 f6k063017_therapix.htm REPORT OF FOREIGN PRIVATE ISSUER

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: June 2017 (Report No. 3)

 

Commission file number: 001- 38041

 

THERAPIX BIOSCIENCES LTD.

(Translation of registrant’s name into English)

 

5 Azrieli Center (Square Tower)

Tel-Aviv 6702501, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒          Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

On June 28, 2017, each of Donald P. Dizon and David Silverman resigned from his position as a member of the Board of Directors (the “Board”) of Therapix Biosciences Ltd. (the “Company”). Mr. Dizon’s and Mr. Silverman’s resignations were not related to any disagreement with the Board on any matter relating to the operations, policies or practices of the Company.

 

On June 28, 2017, the Board appointed Eric So to the Board, effective immediately to fill the vacancy created by the resignation of Mr. Dizon. There are no arrangements or understandings between the Company and any other person pursuant to which Mr. So was selected as a director, nor are there any transactions between Mr. So and the Company in which he has a direct or indirect material interest that the Company is required to report pursuant to the rules and regulations of the Securities and Exchange Commission.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Therapix Biosciences Ltd.

(Registrant)

     
  By   /s/ Josh Blacher
  Name:  Josh Blacher
  Title: Chief Financial Officer

 

Date: June 29, 2017